Justin B. Klee - Sep 30, 2025 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Co-Chief Executive Officer, Director
Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Stock symbol
AMLX
Transactions as of
Sep 30, 2025
Transactions value $
-$430,952
Form type
4
Date filed
10/2/2025, 04:15 PM
Previous filing
Apr 2, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Klee Justin B. Co-Chief Executive Officer, Director C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE /s/ Joshua B. Cohen, as Attorney in Fact 2025-10-02 0001898314

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Sale -$428K -29.8K -0.89% $14.37 3.33M Sep 30, 2025 Direct F1, F2
transaction AMLX Common Stock Sale -$3K -200 -0.01% $15.01 3.33M Sep 30, 2025 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.99 to $14.98. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.